-

The Phadia 2500+ Instrument Family Now Available in the U.S. for Autoimmune Testing

New offering from Thermo Fisher Scientific expands instrument capabilities beyond allergy diagnostics

PORTAGE, Mich.--(BUSINESS WIRE)--The new Phadia 2500+ series of instruments is now available for autoimmune testing in the U.S. The family of high-capacity, intuitive lab instruments supplied by Thermo Fisher Scientific, the world leader in serving science, offers reliable and unparalleled high throughput for both allergy diagnostics and autoimmune testing.

This expanded capability of the Phadia 2500+ series of instruments allows for instrument consolidation and enables additional automation for EliA autoimmune diagnostics, aiding in the diagnosis of autoimmune diseases including Connective Tissue Disease (CTD), Antiphospholipid Syndrome (APS), Celiac Disease, Rheumatoid Arthritis, Autoimmune Liver Disease and Autoimmune Thyroid Disease.

“Increasingly, laboratorians are being asked to further streamline their workflows and become more efficient,” said Michele Zwickl, vice president, commercial operations, U.S., ImmunoDiagnostics, Thermo Fisher. “With the launch of the Phadia 2500+ series, we now offer scalable, high-capacity allergy and autoimmune diagnostics instrumentation that can help large labs be more productive with existing resources.”

The Phadia 2500+ series of instruments is capable of serving laboratories with demands exceeding 10,000 test results every week and maximizes productivity by providing options to run EliA and ImmunoCAP testing in parallel on a single instrument. Its high throughput automation allows laboratories to process up to 480 ImmunoCAP results per hour and up to 300 EliA autoimmunity results per hour.

The series of instruments includes the Phadia 2500 (ImmunoCAP analyzer), Phadia 2500EE (EliA analyzer) and Phadia 2500E (ImmunoCAP and EliA analyzer). For more information on Phadia 2500+ series of instruments, please visit: https://www.thermofisher.com/phadia/us/en/our-solutions/phadia-laboratory-systems/phadia-2500.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Angela Christoforos
508-801-2391
achristoforos@greenough.biz

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Angela Christoforos
508-801-2391
achristoforos@greenough.biz

More News From Thermo Fisher

Nalgene Outdoor Surpasses $1.2 Million in Water Access Impact, Expands Commitment on World Water Day

ROCHESTER, N.Y.--(BUSINESS WIRE)--In America, where refillable water bottles are common, more than 2 million people still lack clean running water at home. To help close that gap, Nalgene Outdoor, maker of reusable water bottles, is expanding its commitment to domestic water access after surpassing $1.2 million in funding and in-kind support since launching the Nalgene Water Fund in 2019. The Fund is committing $50,000 to DigDeep, a national nonprofit advancing equitable water access, matching...

Thermo Fisher Scientific Opens Bay Area Cryo-EM Drug Discovery Center to Accelerate Breakthrough Therapies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the opening of its Cryo-Electron Microscopy (cryo-EM) Drug Discovery Center (CDDC) in South San Francisco. The new center provides pharmaceutical and biotechnology innovators with immersive, hands-on access to advanced cryo-EM technologies designed to accelerate structural insights and the development of life-saving therapies. Accelerating Drug Discovery with Cryo-EM The...

Thermo Fisher Scientific Launches New Color-Based (Chromogenic) Culture Media to Help Detect Candida Infections Faster*, Including Drug-Resistant Candida auris

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of Thermo Scientific™ Brilliance™ Candida 2 Agar and Spectra™ Candida Agar**, new color-based (chromogenic) culture media to help laboratories quickly detect and differentiate clinically important Candida species — including Candida auris, a growing global antimicrobial resistance (AMR) threat1. Invasive fungal infections are an increasing challenge for healthcare systems w...
Back to Newsroom